🟢 Quantum BioPharma is trading 5.3% up today after Rodman & Renshaw initiated coverage with a BUY rating

Quantum BioPharma is trading 5.3% up now at $3.80 after Rodman & Renshaw initiated coverage on September 17, 2026, with a BUY rating and an US$8 price target.

• The analyst coverage is unpaid, and Quantum BioPharma stated it provided no consideration for the report.
• The move also follows the September 16 ArcStone-Kingswood presentation and recent FDA clearance for Lucid-MS Phase 2 trials.
• Broader risk appetite is supportive, with biotechnology and major indexes higher; the initiation is the clearest company-specific catalyst.